



Supplementary Figure. Schematic representation of patient population selected from FUSCC database.

Supplementary Table. Comparison of baseline characteristics by the receipt of ACT in FUSCC cohort

Characteristic	No. of Patients (%)		<i>P</i>
	ACT Group (n=125)	Non-ACT Group (n=112)	
Histology			0.164
Adenocarcinoma	102 (81.6)	83 (74.1)	
Mucinous adenocarcinoma or Signet ring cell carcinoma	23 (18.4)	29 (25.9)	
Gender			0.576
Male	77 (61.6)	65 (58.0)	
Female	48 (38.4)	47 (42.0)	
Tumor location			0.924

Right colon	62 (49.6)	57 (50.9)	
Transverse colon	13 (10.4)	10 (8.9)	
Left colon	16 (12.8)	12 (10.7)	
Sigmoid colon	34 (27.2)	33 (29.5)	
Year of diagnosis			0.026
2008-2011	15 (12.0)	26 (23.2)	
2012-2015	110 (88.0)	86 (76.8)	
Neoadjuvant CT			0.813
No	121 (96.8)	109 (97.3)	
Yes	4 (3.2)	3 (2.7)	
Tumor grade			0.599
Well/moderately differentiated*	92 (73.6)	79 (70.5)	
Poorly differentiated or undifferentiated*	33 (26.4)	33 (29.5)	
Tumor size (cm)			0.194
≤4	48 (38.4)	34 (30.4)	
>4	77 (61.6)	78 (69.6)	
Age at diagnosis (years)			0.020
≤70	99 (79.2)	101 (90.2)	
>70	26 (20.8)	11 (9.8)	

Abbreviation: FUSCC, Fudan University Shanghai Cancer Center; ACT, adjuvant chemotherapy  
Well/moderately differentiated\*: including well differentiated, well-moderately differentiated and well-moderately differentiated

Poorly differentiated or undifferentiated\*: including poorly-moderately differentiated poorly differentiated, and undifferentiated